Devonian Health Group Inc

Research Devonian Health Group Inc (GSD) on Bullrun: market cap CAD 31.15M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is CAD 31.15M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025CAD 18.52M-CAD 6.97M-CAD 6.22M38.4%n/aCAD 6.64MCAD 114.22KCAD 9.60M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-23CAD 31.15Mn/an/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 CAD.

About Devonian Health Group Inc

Devonian Health Group Inc. operates as a clinical stage biopharmaceutical corporation with novel therapeutic approaches targeting unmet medical needs in Canada and Internationally. It engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Devonian Health Group Inc's market cap?

Devonian Health Group Inc's market capitalization is CAD 31.15M.

What does Devonian Health Group Inc do?

Devonian Health Group Inc. operates as a clinical stage biopharmaceutical corporation with novel therapeutic approaches targeting unmet medical needs in Canada and Internationally. It engages in the development of botanical drugs.